echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Front Cardiovasc Med: Biejia Ruanmai Decoction inhibits retinal neovascularization in diabetic mice by inducing apoptosis of retinal vascular endothelial cells

    Front Cardiovasc Med: Biejia Ruanmai Decoction inhibits retinal neovascularization in diabetic mice by inducing apoptosis of retinal vascular endothelial cells

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Objective: Proliferative diabetic retinopathy (PDR) is one of the main complications of diabetes, which is mainly caused by the abnormal proliferation of retinal vascular endothelial cells and the formation of new blood vessel.


    Methods: Diabetic mice model of PDR was established by feeding a high-fat and high-sugar diet and intraperitoneal injection of streptozotocin (STZ, 50 mg/kg.


    Simultaneously, high glucose-exposed human retinal capillary endothelial cells (HRCECs) were used to simulate PDR in vitr.


    RESULTS: In vivo experiments showed that BJ inhibited the formation of acellular capillaries, decreased the expression of VEGF, and increased the level of ZO-1 in the retina of diabetic mic.


    Conclusion: BJ inhibited the formation of cell-free capillaries and the instability of retinal structure in the retina of DR mice by inducing cell cycle arrest and reducing mitochondrial membrane potential, inhibited the proliferation of high glucose-exposed HRCECs, and induced apoptosis, indicating that BJ has the potential to treat D.


     

    Source:

    Liu QP, Chen YY, Yu YY, et a.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.